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ABSTRACT
Objectives To assess and compare the cost effectiveness
of three different strategies for prenatal screening for
Down’s syndrome (integrated test, sequential screening,
and contingent screenings) and to determine the most
useful cut-off values for risk.
Design Computer simulations to study integrated,
sequential, and contingent screening strategies with
various cut-offs leading to 19 potential screening
algorithms.
Data sources The computer simulation was populated
withdatafromtheSerumUrineandUltrasoundScreening
Study (SURUSS), real unit costs for healthcare
interventions, and a population of 110948 pregnancies
from the province of Québec for the year 2001.
Main outcome measures Cost effectiveness ratios,
incremental cost effectiveness ratios, and screening
options’ outcomes.
Results The contingent screening strategy dominated all
otherscreeningoptions:ithadthebestcosteffectiveness
ratio ($C26833 per case of Down’s syndrome) with fewer
procedure related euploid miscarriages and unnecessary
terminations (respectively, 6 and 16 per 100000
pregnancies).Italsooutperformedserumscreeningatthe
second trimester. In terms of the incremental cost
effectiveness ratio, contingent screening was still
dominant: compared with screening based on maternal
agealone,thesavingswere$C30963peradditionalbirth
withDown’ssyndromeaverted.Contingentscreeningwas
the only screening strategy that offered early reassurance
to the majority of women (77.81%) in first trimester and
minimised costs by limiting retesting during the second
trimester (21.05%). For the contingent and sequential
screening strategies, the choice of cut-off value for risk in
the first trimester test significantly affected the cost
effectiveness ratios (respectively, from $C26833 to
$C37260 and from $C35215 to $C45314 per case of
Down’s syndrome), the number of procedure related
euploid miscarriages (from 6 to 46 and from 6 to 45 per
100000 pregnancies), and the number of unnecessary
terminations(from16to26andfrom16to25per100000
pregnancies).
Conclusions Contingent screening, with a first trimester
cut-off value for high risk of 1 in 9, is the preferred option
for prenatal screening of women for pregnancies affected
by Down’s syndrome.
INTRODUCTION
In the past 10-15 years, major advances have been
made in prenatal screening for Down’s syndrome,
12
the foremost known genetic cause of mental
retardation.
3 It has been suggested that maternal age
aloneasascreeningstrategyshouldbeabandoned,
4but
there is still no consensus on the most cost effective
alternative, and thus no national strategy exists in the
United States or Canada.
56
New strategies that allow a relatively high detection
rate combine analyses from first and secondtrimesters
of pregnancy.
78 Different approaches have been
proposed
679such as
 The integrated test, in which the results from
first trimester screening tests are not analysed
until the results from second trimester tests are
evaluated, when both sets are assessed together
1
 Sequential screening, in which first trimester
screening results determine whether second
trimester testing is indicated: women with a
positive first trimester result are offered invasive
testing (chorionic villous sampling), whereas
those with a negative result are offered another
serum test
10
 Contingent screening, in which the first
trimester screening results are used to categorise
women as high, intermediate, or low risk.
11 High
risk women are offered early diagnosis
(chorionic villous sampling), low risk women
are reassured and do not undergo second
trimester testing, and intermediate risk women
are offered second trimester testing. The cut-off
values between the risk categories vary
depending on how the groups are defined.
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for Down’s syndrome have primarily focused on the
detection rates of the different strategies used.
6
Although the detection rate is important for indivi-
duals, the cost effectiveness ratio and similar end
points of screening strategies are needed for the
development of optimal public health strategies.
6 In
thatrespect,onlycontradictoryandlimiteddataexist
on the three above methods of combining first and
second trimester tests.
69 Using a decision analysis
model based on data from the First and Second
Trimester Evaluation of Risk (FASTER) trial,
12 Ball
et al reported that contingent screening dominated
(lower costs with better outcomes) the integrated
test.
6 In contrast, Wald et al—summarising the
modelling of integrated, sequential, and contingent
screening strategies from data derived from the
Serum Urine and Ultrasound Screening Study
(SURUSS)
13—concluded that integrated screening
had the best screening performance.
9 However,
recent reports underline the insufficiency of data on
these three screening strategies.
5914 For sequential
and contingent testing, there is no consensus on cut-
off levels, resulting in variations in performance
measured.
8 A workshop of experts convened by the
National Institutes of Health concluded that the
contingent screening strategy needed further study
before its widespread implementation could be
recommended.
8
Giventhecountlessscreeningstrategiesavailable,
715
regionaldifferences inlocal resources,
51 6and the costs
ofprospectiveclinicalstudies,
17noempiricalstudycan
be foreseen that would compare all options available
forthethreeapproachestocombiningfirstandsecond
trimesteranalyses.Thereareindeedtoomanypossible
combinations of tests, sequences, cut-off values, and
schedules to be handled in a single study. Only
computer simulations can compare all the options to
identify the most cost effective.
6917-19
In the current analysis, we performed computer
simulations to compare 19 different screening options
based on the three screening approaches (integrated
test and sequential and contingent screenings) with
various cut-off levels and using real data from the
SURUSS trials.
913Our aims were to
 Analyse the cost effectiveness ratio of the
different screening options from a public health
perspective
 Compare their performance estimates for an
overall 90% detection rate by evaluating seven
other relevant end points that cover the main
outcomes in prenatal screening for Down’s
syndrome
917:
1) False positive rate that defines the number of
scheduled amniocentesis procedures
2) Number of procedure related miscarriages of
normal (euploid) fetuses
3) Number of live births with Down’s syndrome
4) Number of unnecessary terminations
5) Proportion of pregnancies affected by
Down’s syndrome that were screened by a first
trimester test
6) Proportion of patients reassured early in
gestation by first trimester testing
7) Proportion of continuing pregnancies that
proceed to a second trimester test
 Compare the effects of eight different first
trimester cut-off values in contingent and
sequential screening strategies to determine the
optimal value.
MATERIAL AND METHODS
Screening strategies and tests
The screening strategies considered were the inte-
grated test, sequential screening, and contingent
screening compared with maternal age alone
(≥35 years), which has been the standard since
antenatal diagnosis guidelines for invasive testing
were establishedinthe USin the late 1970s,
20and the
triple test, whichhas beenwidelyavailable in Europe
and Canada since 1991.
81621 The box gives further
details of the screening strategies and the tests used.
Sequential and contingent screening strategies
c o n s i s to fas e q u e n c eo ft e s t sw i t hm a n yp o s s i b l e
cut-off values for the risk of the fetus having Down’s
syndrome, but screening performance has been
reported for only eight different cut-off points for
f i r s tt r i m e s t e rt e s t s( 1i n6 ,1i n9 ,1i n3 0 ,1i n5 8 ,1i n
114, 1 in 175, 1 in 237, and 1 in 307).
9 We compared
19 screening algorithms comprised possible screen-
ing scenarios resulting from the three screening
Definitions of screening procedures
Integrated test
Measurements performed at different times of pregnancy are integrated into a single test
result. Unless otherwise qualified, it refers to the integration of nuchal translucency
measurement(byultrasoundscanofthewidthofanareaoftranslucencyatthebackofthe
fetalneck)andmeasurementofpregnancyassociatedplasmaproteinA(PAPP-A)inthefirst
trimesterwiththequadrupletestmarkersinthesecondtrimester(measurementofmaternal
serum concentrations of α fetoprotein, unconjugated oestriol, free or total β human
chorionic gonadotrophin, and inhibin A) together with maternal age.
Sequential screening
First trimester tests are performed (nuchal translucency measurement and PAPP-A) and
interpreted immediately. If the result is positive, the mother is offered a diagnostic test
(chorionic villous sampling), but if it is not positive, second trimester serum markers
(quadruple test markers) are measured and the results combined with the first trimester
results to form an integrated test.
Contingent screening
Firsttrimestertests(nuchaltranslucencymeasurementandPAPP-A)areused tocategorise
pregnant women as high, low, or intermediate risk. High risk women (positive result) are
immediatelyofferedadiagnostictest(chorionicvilloussampling),lowriskwomen(negative
test result) receive no further screening, and intermediate risk women (lower risk positive
result)undergosecondtrimesterscreening(quadrupletestmarkers)foranintegratedtestto
be done.
Triple test
Second trimester test based on the measurement of maternal serum α fetoprotein,
unconjugated oestriol, and free or total β human chorionic gonadotrophin, together with
maternal age.
RESEARCH
page 2 of 10 BMJ | ONLINE FIRST | bmj.comstrategies (integrated test and sequential and con-
tingent screening), different cut-off values for con-
tingent and sequential screenings, the triple test, and
maternalagealone.Forcontingentscreening,wealso
used a lower risk cut-off of 1 in 2000.
Diagnostic tests
The diagnostic procedures included in our simula-
tion were conditional on the stage of pregnancy in
accordance with best practice in prenatal care. Thus,
amniocentesis was used for prenatal diagnosis only
after second trimester screenings results, whereas
women with a positive result at the first trimester
screening were considered for transabdominal chor-
ionic villous sampling for caryotyping. Timing of
procedure-relatedeuploidmiscarriagesisdependent
on the test undergone. Our computer model also
accounted for the performance characteristics of the
diagnostic tests (amniocentesis and chorionic villous
sampling).
Decision model
We developed a computer program in C11 language
that simulates all 19 screening scenarios. The program
was devised to
 Generate a virtual population with
characteristics related to the prevalence and
clinical course of pregnancies affected by
Down’s syndrome and unaffected pregnancies,
as well as maternal age distribution
 Construct the various screening algorithms for
the screening and diagnosis options for Down’s
syndrome
 Simulate screening of this virtual population
with each algorithm and measure pregnancy
outcomes
 Establish the direct healthcare costs of each
screening option using costs of procedures and
of complications provided by the Ministry of
Health.
Figure1showsasimplifiedversionofthedecision
model. The model includes several possible out-
comes of screening and diagnostic testing decisions,
including birth of a baby with no chromosomal
disorder, birth of a baby with Down’s syndrome,
miscarriage, elective abortion after positive test
results, and whether a pregnancy loss occurs after a
diagnostic test.
Data used in analysis
Table 1 lists all the input variables and their data
sources.Table 2showsthedemographiccharacteristics
of the virtual population used in our computer
simulation and the most critical assumptions.
Our virtual population of 110948 pregnancies corre-
sponded to all pregnancies in Québ e cp r o v i n c ei ny e a r
2001
2223 with the same maternal age distribution. This
population was of mixed origins, mainly white, and
table 2 contains details of maternal ages.
Probabilities
Pregnancies affected by Down’s syndrome and risk of
miscarriage—We estimated the risk of a pregnancy
beingaffectedbyDown’ssyndromebymultiplyingthe
specificoddsbymaternalageofhavinganaffectedlive
birth
2425 (corrected for the spontaneous miscarriage of
fetuses with Down’s syndrome
2627) by the likelihood
ratio (for a given set of marker values) obtained from
the overlapping multivariate Gaussian distributions of
marker levels in affected and unaffected pregnancies.
9
Ifawomanchoosestoundergoamniocentesis,sheisat
risk of a miscarriage before she has the test and either
before or after the test results are given.
Testperformance—Weusedthedistributionofmarker
values in pregnancies affected by Down’s syndrome
andinunaffectedpregnanciesreportedintheSURUSS
trials to determine the parametric values (means,
standard deviations, correlation coefficients, and trun-
cationlimits).
913Weincludedratesoffalsepositiveand
false negative test results in the calculations.
Table 1 |Input variables used in computer simulation of 19 different screening options in
prenatal screening for Down’ss y n d r o m e
Input variables Value Data sources
Costs of procedures Costs ($C)*
Integrated test 65.00
MSSS (2005),
30 (2007),
31
RAMQ (2007)
33
Sequential screening 105.00
Contingent screening 55.00
Triple test 15.00
Consulting with a genetic counsellor 73.90 RAMQ (2007)
33
Chorionic villous sampling 876.00 MSSS (2005),
30 (2007),
31
RAMQ (2005),
33 (2007)
33 Amniocentesis 500.00
Termination of pregnancy 1357.33 MSSS (2003)
29
Screening tests with 90% detection rate False positive rate (%)
Integrated test (1/245 cut-off value) 2.60 Wald et al (2003)
13
Sequential screening, cut-off values for first
trimester test:
Wald et al (2006)
9
1/6 2.11
1/9 2.12
1/30 2.25
1/58 2.46
1/114 2.97
1/175 3.65
1/237 4.42
1/307 5.23
Contingent screening, cut-off values for first
trimester test:
Wald et al (2006)
9
1/6 2.29
1/9 2.29
1/30 2.42
1/58 2.62
1/114 3.11
1/175 3.74
1/237 4.47
1/307 5.27
Triple test (1/690 cut-off value) 14.70 Wald et al (2003)
13
*Canadian dollars ($C), exchange rate in 2007: $C1.0748=$US1.00.
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of compliance previously estimated in the Québec
population
28—that is, the proportion of women who
consenttoparticipateinprenatalscreeningforDown’s
syndrome and to a diagnostic test after a positive
screening result. We also included the chance that a
woman will choose elective abortion after a positive
diagnostic test.
28
Costs
In Canada, in accordance with the Canadian Health
Care Act, all services considered as medically neces-
sary are generally provided exclusively inside the
public healthcare system and are free of charge. We
considered only direct costs under the Ministry of
HealthandthePublicMedicalAssuranceperspectives.
Unit prices were averages for Quebec province
calculated from government databases (financial and
operative databank SIFO and APR-DRG). Costs for
laboratory and imaging tests were from technicalunits
for Quebec province.
29-33 Theseunit pricesinclude the
costs of necessary support services (such as adminis-
tration, security, cleaning, etc).
34 Items considered for
costingcomprisedscreeningcostsandmedicalservices
relatedtothe followingoutcomes—birth,spontaneous
miscarriage,electiveabortionafterpositivetestresults,
or pregnancy loss after a diagnostic test. Costs are
expressed in Canadian dollars ($C) at 2007 values
(exchange rate: $C1.0748=$US1.00).
Cost effectiveness analysis
Our approach follows guidelines for cost effectiveness
analysis in prenatal diagnosis.
17 The analyses were run
to evaluate global costs, cost effectiveness ratios (costs
per case of Down’s syndrome diagnosed), and incre-
mental cost effectiveness ratios comparing all 19
screening options. Incremental cost effectiveness
ratio was calculated by dividing the difference in cost
between each screening strategy and screening based
on maternal age only (amniocentesis for women aged
≥35 years) by the difference in the number of cases of
Down’s syndrome detected by the two strategies. The
incremental cost effectiveness ratio therefore repre-
sents the additional cost or savings per additional
abnormality detected. All measured costs occurred
within one year; and so there was no need to discount
costs and effects over time.
17
Sensitivity analyses
In order to test the robustness of our findings, we
performedaseriesofsimulations(univariatesensitivity
analyses) in which we varied the major assumptions of
the modelling with values proposed in the AETMIS
report
22andrecalculatedthecosteffectivenessratios.
17
Apartfromthevaluesshownintables 1and2,wealso
tested the effects of
 Rates of consent to participate in prenatal
screening of 65% and 80%
22
 Rates of fetal loss from chorionic villous
sampling of 0.5%, 1%, and 2%, and from
amniocentesis of 1% and 1.5%
22
 The proportion of couples with a fetus with
confirmed Down’s syndrome who would
undergo pregnancy termination, namely 70%
and 80%
 Varying the sensitivities and false positive rates
of the screening strategies over the ranges
achieved in the SURUSS trial.
913
Estimation of confidence intervals
In order to generate 95% confidence intervals for our
estimates of cost effectiveness ratios, we used the
method of replications.
35 This consisted of simulating
eachscreeningoption100timesonavirtualpopulation
of 110948 pregnancies (100×110948 individuals). It
resulted in more than 11 million individuals being
screened for computing the mean cost effectiveness
ratios for each screening scenario.
RESULTS
Cost effectiveness analysis
Table 3summarisestheresultsofourcosteffectiveness
analysis. The most cost effective screening strategy
seems to be contingent screening (cost effectiveness
ratio $C26833 per case of Down’s syndrome with a
high risk cut-off value of 1 in 30). These results were
robust in sensitivity analyses: none of these different
Table 2 |Demographic characteristicsofthe populationandthe mostcriticalassumptionsused
in computer simulation of 19 different screening options in prenatal screening for Down’s
syndrome
Characteristics Value Data sources
Population simulated
Total No of pregnant women 110 948 MSSS (2007)
23
No of pregnancies affected by Down’s
syndrome:
AETMIS(2003),
22Snijders(1999),
27
Morris et al (1999)
55
At first trimester 290
At second trimester 190
At third trimester 140
At birth 131
No of women by age (years):
MSSS (2007)
23
<20 9 008
20-24 24 987
25-29 33 421
30-34 27 320
35-39 13 135
40-44 2 925
≥45 157
<35 years old 94 735
≥35 years old 16 213
Mean maternal age (years) 27
Assumed probabilities (%)
Consent to participate in prenatal screening 70.0
Forest et al (2004)
28 Consentforamniocentesisorchorionicvillous
sampling with screening positive
90.0
Fetal loss from amniocentesis 0.5 AETMIS (2003),
22 Sundberg et al
(1997),
56 CETS (1997)
57 Fetal loss from chorionic villous sampling 1.6
Proportion who terminated pregnancy with
fetal Down’s syndrome
90.0 Forest et al (2004)
28
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screening scenarios analysed. Compared with the
reference screening strategy (maternal age only), the
incremental cost effectiveness ratio of contingent
screening (with cut-off value of 1 in 6) is −$C30963
p e ra v e r t e db i r t hw i t hD o w n ’ss y n d r o m e .T h e
estimated costs per prevented birth with Down’s
syndrome were $C35215 for sequential screening,
$C38944 for integrated screening, and $C43809 for
the triple test. Consequently, the contingent screening
strategy seems to be most cost effective. As expected,
amniocentesisbasedonadvancedmaternalageonlyis
the least cost effective option, with a cost effectiveness
ratio of $C74037 per case of Down’s syndrome.
Screening strategies outcomes
Depending on the specific end points that are
considered, different screening approaches may seem
moreappropriate.Themostappropriatescreeningtest
for Down’s syndrome should have the lowest false
positive rate (to minimise the number of invasive
procedures required and their related complications),
the highest detection rate, and the best cost effective-
ness ratio.
16 The screening procedure (non-invasive
screeninganddiagnostictechnique)mayalso interfere
with the numberof live births with Down’s syndrome.
Figure 2 shows the effects of the different screening
strategies on these major end points—false positive
rate, number of procedure-related euploid miscar-
riages, and number of live births with Down’s
syndrome.
Early diagnosis of pregnancies affected by Down’s
syndrome may result in unnecessary terminations
since some of the affected fetuses would be sponta-
neously aborted before term.
9 Some studies have
suggest that, in order to avoid this problem, women
prefer a lower false positive rate,
3637 but others suggest
thatwomenwantearlydiagnosis.
3839Weevaluatedthe
effect of the different screening strategies on this issue
by calculating the number of unnecessary termina-
tions, the proportion of pregnancies affected by
Down’s syndrome screened by a first trimester test,
and the proportion of continuing pregnancies that
proceed to a second trimester test (fig 3).
Contingent and sequential screening strategies
produced similar results on the major outcomes—
respectively, 1.43%and1.55%forfalsepositiveresults
(fig2),sixprocedurerelatedeuploidmiscarriageseach
(fig 2), 16 unnecessary terminations each (fig 3), and
43.71% and 44.13% of affected pregnancies with a
positivefirsttrimestertest(fig3)(theseresultsarethose
achieved with the most favourable cut-off value).
However, contingent screening was unique in permit-
ting 77.81% of patients to be reassured at the first
trimester and 77.95% of women to avoid retesting in
the second trimester (proportion of continuing preg-
nanciesthatproceedtoasecondtrimestertesting,fig3).
Indeed, contingent screening (whatever the cut-off
value) allowed about 78% of women (77.75% to
78.51%) to be reassured with a negative screening
result early in gestation, which was obviously not
A: Algorithm for screening options
B: Algorithm for diagnosis procedure
Cohort of
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pregnant
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Integrated
test
Sequential
strategy
Screening
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accept
Contingent
strategy
Triple
test
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negative
First
trimester
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see panel B
see panel B
see panel B
see panel B
see panel B
First
trimester
negative
First trimester
high risk
positive
First trimester
high risk
negative
First trimester
moderate risk
positive
First trimester
moderate risk
negative
Additional
second
trimester
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Additional
second
trimester
negative
Live birth
Still birth
Live birth
Still birth
Live birth
Still birth
see panel B
Live birth
Still birth
Live birth
Still birth
Live birth
Still birth
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Still birth
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Still birth
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Still birth
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Triple test
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negative
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Fetal loss
from diagnosis
Screening
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accept
Screening
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Screening
consent
reject
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consent
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Diagnosis
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Live birth
Still birth
Live birth
Still birth
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Terminate
pregnancy
Live birth
Diagnosis test
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Fetal loss
from diagnosis
Diagnosis
consent
accept Diagnosis
test
negative
Diagnosis
consent
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Fig 1 | Simplified version of the decision model for screening options (panel A) and diagnosis
procedure (panel B) used in computer simulation of prenatal screening strategies for Down’s
syndrome. Not shown, but included in the real model, is the possibility that miscarriage occurs
before testing or after test results are known
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strategies.
In the same manner, we found that integrated
screening was associated with a low number of
procedure related euploid miscarriages (n=6, fig 2)
and, in conjunction with the triple test, gave the best
resultforunnecessaryterminations(n=6forboth,fig3).
Moreover, the integrated test’s false positive rate is
close to those achieved by sequential and contingent
screening (1.82%, 1.43%, and 1.55% respectively,
fig 2).
Impact of cut-off values in first trimester screening
We simulated the use of different cut-off values for the
risk of a fetus having Down’s syndrome in the first
trimester tests of the contingent and sequential screen-
ing strategies. For both contingent and sequential
screening, these had significant effects on
 Cost effectiveness ratios (from $C26833 to
$C37260 and from $C35215 to $C45314 per
case of Down’s syndrome respectively, table 3)
 False positive rate (1.55% to 3.69% and 1.43% to
3.66%, fig 2)
 Number of procedure related euploid
miscarriages (6 to 46 and 6 to 45, fig 2)
 Number of unnecessary terminations (16 to 26
and 16 to 25, fig 3)
 Proportion of affected pregnancies with a
positive result from the first trimester test
(44.1% to 86.1% and 43.7% to 86.3%, fig 3).
DISCUSSION
Limitations of study
Our results are based on mathematical modelling and
not on prospective observational data. However, we
used empirical data and true healthcare costs as input
parameters for the simulations. Given geographical
limitations, resource differences between regions, and
the many possible screening strategies for Down’s
syndrome, it is unlikely that a large scale, comprehen-
sive, prospective, clinical trial could be organised
across North America. Our approach was useful in
allowing 19 different strategies to be assessed and
compared simultaneously.
1840-42
Our reportedcosteffectivenessratioswere basedon
Québec province’s healthcare system and costs.
However, given the robustness of our findings
observedinthesensitivityanalyses(inwhichwevaried
the values of the major assumptions of the modelling),
our conclusions are likely to be applicable to other
jurisdictions. The demographic characteristics of the
population we simulated are similar to those of other
Western countries. In particular, the mean maternal
ageand the proportionof womenaged ≥35 yearswere
similar to those ofthe populations ofthe SURUSSand
the FASTER trials, which represented women in the
UK and US.
1213 The effect of the maternal age
distributiononthe detectionrateofDown’ssyndrome
is reported to be limited and unlikely to be large
enoughtoinfluencescreeningpolicydecisions.
43Also,
pregnancy outcomes are likely to be similar across
differentpopulations.Withrespecttohealthcarecosts,
they could be estimated for other provinces by using
other costs units in the simulation model.
Most improvements in overall cost effectiveness
attained with a screening strategy are due to the
reduction in live births with Down’s syndrome.
18 An
important drawback of studies that incorporate the
futurecostsofcaringforachildwithDown’ssyndrome
into their cost effectiveness or cost utility analyses
644is
thattheydonotincorporatecommensuratebenefitsof
having such a child.
45 In accordance with previous
reports,
946-48 we decided not to consider the cost of
caring for a child with Down’s syndrome. However,
computing the cost per case of Down’s syndrome
detected allows us to compare different screening
strategies on a common ground.
Our study did not consider the logistical problems
and costs of implementing a screening strategy that
includes nuchal translucency measurement or chor-
ionic villous sampling in North America.
815 Neither
technique is universally available throughout the US
andCanada,
1518andthecostofestablishingascreening
programme with mandatory use of the techniques,
includingitsadministrativeandtechnicalchallenges,is
unknown.
1550 Because of this, some have speculated
that such a screening programme is not justifiable
15 or
has serious implications for resource use.
16
Table 3 |Cost effectiveness analysis of different screening options in prenatal screening for
Down’ss y n d r o m e *
Screening options
Global costs
($Cmillions)† Effectiveness‡
Cost effectiveness
ratio
Incremental cost
effectiveness ratio
Amniocentesis for
women ≥35 years old
4.1549 56.12 74 037 1.00
Contingent screening,
cut-off values for first
trimester test:
1/6 2.7529 101.40 27 149 −30 963
1/9 2.7630 102.48 26 961 −30 025
1/30 2.8579 106.51 26 833 −25 739
1/58 2.9960 108.67 27 570 −22 054
1/114 3.2596 109.72 29 708 −16 704
1/175 3.5509 111.69 31 792 −10 871
1/237 3.8494 111.61 34 490 −55 0 6
1/307 4.1999 112.72 37 260 795
Sequential screening,
cut-off values for first
trimester test:
1/6 3.6265 100.88 35 949 −11 805
1/9 3.6400 101.63 35 816 −11 315
1/30 3.7440 106.32 35 215 −81 8 5
1/58 3.8662 109.07 35 447 −54 5 3
1/114 4.1326 108.78 37 991 −423
1/175 4.4416 112.37 39 526 5 096
1/237 4.7597 110.62 43 027 11 096
1/307 5.0960 112.46 45 314 16 704
Integrated test 3.3944 87.16 38 944 −24 502
Triple test 3.8324 87.48 43 809 −10 285
*Values are per 100000 pregnancies in prenatal care for an overall 90% detection of cases of Down’s syndrome.
†Canadian dollars ($C), exchange rate in 2007: $C1.0748=$US1.00.
‡No of cases of Down’s syndrome detected by screening test.
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options
Thereisnoconsensusonwhatarethemostappropriate
cut-off valuesfor high risk in the first trimester tests for
contingent and sequential screening strategies,
8 even
though they could have a major effect on screening
performance.
69Our data show the impact of modulat-
ing the cut-off values and confirm that, for risk
assessment to be successful, a careful choice of cut-off
is required.
The first aim of using non-invasive screening is to
reduce the number of procedure related euploid
miscarriages.
50Ouranalysissuggeststhatfirsttrimester
cut-off values for high risk of 1 in 6 and 1 in 9 are most
appropriate because they lead to the same number of
procedure-related euploid miscarriages as occurs with
the integrated test (which is considered the optimum
screening option for limiting the procedure related
euploid miscarriages
9). With these cut-off values,
contingent screening remains more cost effective than
theintegratedtestandsequentialscreening.Ourresults
are consistent with those of Wald et al,
9 who reported
that,withafirsttrimestercut-offpointforhighriskof1
in 30, the number of procedure-related euploid
miscarriages was greater in contingent and sequential
screening options than in the integrated test, and that
contingentscreening,butnotsequentialscreening,was
more cost effective than the integrated test.
9
For contingent screening, the optimal cut-off value
seems to be 1 in 9 cut-off with regard to cost
effectiveness. The cut-off value of 1 in 30 showed the
bestcost effectivenessratio,whereasthe valueof1in 6
produced the best incremental cost effectiveness ratio:
hence,aninbetweenvalueof1in9shouldachievethe
best balance between these performance measures.
This value has important implications because the
first trimester cut-off values traditionally used by
healthcare professionals are much lower. Before the
development of new screening strategies that combine
first and second trimester tests,
78 only the combined
test (first trimester measurement of nuchal translu-
cency, pregnancy associated plasma protein A, and β
humanchorionic gonadotrophin)useda firsttrimester
cut-offvalue.Thevalueforthistest,whichhasbecome
thedefactostandardofcareintheUKandmayspread
in North America,
651 is 1 in 670 for obtaining a 90%
detection rate.
13 With strategies that combine first and
second trimester tests,
78 healthcare workers would
have to be prepared (and trained) for the use of the
much higher level of 1 in 9, and appropriate informa-
tionwouldbeneededforpatients.Risklevelsareoften
misunderstood by patients,
52 and it may be difficult to
refuse a diagnostic test at first trimester for an anxious
woman with a calculated risk close to the 1 in 9 cut-off
point because some women want an early
diagnosis.
3839 However, the use of inappropriate cut-
offvaluesinthefirsttrimestermayproduceanexcessin
iatrogenic losses and costs.
Different screening strategies
Contingent screening
Our results confirm previous reports
6 that contingent
screening dominates all other options:
 Best cost effectiveness for achieving a lower
overall false positive rate leading to better
outcomes
 Fewer procedure related euploid miscarriages
and unnecessary terminations
 Lowest cost per case of Down’s syndrome
detected
 Best incremental cost effectiveness ratio.
Contingent screening also offers early testing to
thosemostlikelytohaveanaffectedpregnancy(asdoes
sequential screening), and it is the only option that
allows the majority of women to be reassured early in
gestation. Furthermore, it minimises costs by limiting
retestingat the secondtrimester.Avoidingsuchrepeat
bloodtestsisamajorreductioninunneededclinicvisits
and their attendant costs. In our model, starting with
110948 pregnancies, the removal of about 86484
second clinic visits, blood draws, and reagent costs,
results in major cost savings. Additionally, savings to
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Fig 2 | Effects of different prenatal screening strategies for Down’s syndrome on (A) rate of false
positive results, (B) number of procedure related euploid miscarriages, and (C) number of live
births with Down’s syndrome (all values are per 100000 pregnancies)
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to be ignored.
5
It has been proposed that all women who screen
negativeatthefirsttrimesterwillstillrequirescreening
atthesecondtrimesterforneuraltubedefects
8andthat
this may affect the cost effectiveness of contingent
screening.
9However,thisisnotapplicableinourstudy
since the standard practice in Canada and similar
countries is that all women undergo a fetal ultrasound
assessmentat20weeksofgestation,
550sothatasecond
trimester test for serum α fetoprotein seems to be
unnecessary.
5
Sequential screening
In accordance with reported data,
69we found sequen-
tial screening to be outperformed by contingent
screening. This is probably due to the high proportion
ofwomenwhoproceedtoasecondtrimestertestunder
the sequential screening scenario. However, the
contingent and sequential screening options are very
similar with regard to other outcomes.
Integrated test
Our results confirm reports that the integrated test
results in few procedure related euploid miscarriages
9
and that its principal advantage is the low number of
unnecessary terminations (because this screening
option allows a diagnostic test only in the second
trimester). However, the integrated test does not allow
identification of affected pregnancies at the first
trimester, nor reassurance for women with unaffected
pregnancies. This could be a disadvantage given that
women seem to want an early diagnosis.
3839
Triple test
Consideringcosteffectivenessandoutcomes,tripletest
has too many limitations to be maintained as a
desirable Down’s syndrome screening strategy. But a
screening option that starts in second trimester should
also be available because one third of women seek
prenatal care after the first trimester.
7
Amniocentesis for women aged ≥35 years
We show here that scheduling an amniocentesis for
women aged ≥35 years is not a cost effective strategy
and should be abandoned rapidly. Also, this approach
may produce seven times more procedure related
euploid miscarriages than contingent screening.
What screening option?
We conclude that, depending on local conditions,
16
contingentscreeningisthepreferredscreeningstrategy
forDown’ssyndromewithafirsttrimestercut-offvalue
for risk of 1 in 9. Obviously, if it becomes possible to
perform non-invasive prenatal diagnosis of Down’s
syndrome by means of fetal DNA or cells in maternal
blood new cost effectiveness studies will be
needed.
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